Antje WilluweitDirector of Preclinical Development at Priavoid GmbHSpeaker
Profile
Antje Willuweit is Director of Preclinical Development and Co-founder of Priavoid GmbH, Düsseldorf, Germany, since 2017. She received her PhD in Biology from the University of Darmstadt, Germany, while working at the Max-Planck-Institute in Bad Nauheim, Germany. Next, she gained 9 years of industrial experience in several Biotech companies before joining the Jülich Research Centre in 2011 at the Institute of Neuroscience and Medicine, where she established her own research group. In 2025, she received her habilitation from the Heinrich-Heine-University of Düsseldorf. In total, she has got over 25 years of experience with animal models, including 20 years in the field of preclinical drug testing against Alzheimer´s disease and other neurodegenerative diseases. Her current focus is the development of peptides targeting misfolded proteins triggering neurodegeneration.
Agenda Sessions
Targeting Neurodegenerative Diseases with Priavoid’s Peptide Drug Development Platform
, 15:00View Session

